Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bufonis venenum injection for severe COVID-19 pneumonia
ChiCTR2000030704Phase 4Suspended
- Sponsor
- The First People's Hospital of Jiangxia District, Wuhan
- Start
- Feb 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label trial of cinobufacini in coronavirus pneumonia (2 arms), sponsored by The First People's Hospital of Jiangxia District, Wuhan. Primary endpoints: PO2/FiO2 and ROX index. Started Feb 2020; status: suspended.
02
Drugs
cinobufacini
03
Conditions
coronavirus pneumonia
Beyond the preview
Go deeper on ChiCTR2000030704.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2000030704.